What's in Valneva Austria GmbH's pipeline?

Valneva Austria GmbH has 18 drugs in our index: 0 marketed, 0 filed, 7 in Phase 3, 7 in Phase 2, 4 in Phase 1.

Which companies overlap with Valneva Austria GmbH's portfolio?

Top competitors by shared drug class: Merck Sharp & Dohme LLC, GlaxoSmithKline, Green Cross Corporation, Bharat Biotech International Limited, Boryung Pharmaceutical Co., Ltd.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/valneva-austria-gmbh.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Valneva Austria GmbH — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Valneva Austria GmbH pipeline: 0 marketed, 0 filed, 7 Phase 3, 7 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 7 Phase 3 7 Phase 2 4 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Biological Vaccine VLA1553	Biological Vaccine VLA1553	phase 3	Inactivated viral vaccine	Chikungunya virus structural and non-structural antigens	Immunology / Infectious Disease
Japanese Encephalitis purified inactivated vaccine	Japanese Encephalitis purified inactivated vaccine	phase 3	Inactivated viral vaccine	Japanese encephalitis virus antigens	Infectious Disease / Immunology
Havrix®720	Havrix®720	phase 3	Inactivated viral vaccine	Hepatitis A virus antigen	Immunology / Infectious Disease
IC51	IC51	phase 3	Therapeutic vaccine	Human papillomavirus (HPV) antigens	Oncology / Immunology
IC51 Japanese Encephalitis	IC51 Japanese Encephalitis	phase 3	Inactivated viral vaccine	Japanese encephalitis virus	Infectious Disease / Immunology
VLA1553	VLA1553	phase 3	vaccine		Infectious Disease
VLA2001 - adolescent part	VLA2001 - adolescent part	phase 3	vaccine	SARS-CoV-2 spike protein	Infectious Disease

Therapeutic area mix

Immunology / Infectious Disease · 2
Infectious Disease · 2
Infectious Disease / Immunology · 2
Oncology / Immunology · 1
Vaccines · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Merck Sharp & Dohme LLC · 4 shared drug classes
GlaxoSmithKline · 4 shared drug classes
Green Cross Corporation · 3 shared drug classes
Bharat Biotech International Limited · 3 shared drug classes
Boryung Pharmaceutical Co., Ltd · 3 shared drug classes
Jiangsu Province Centers for Disease Control and Prevention · 3 shared drug classes
China National Biotec Group Company Limited · 3 shared drug classes
Pfizer · 3 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Valneva Austria GmbH:

Cite this brief

Drug Landscape (2026). Valneva Austria GmbH — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/valneva-austria-gmbh. Accessed 2026-05-16.